'Pharma Bro' Martin Shkreli Arrested on Securities Fraud Charges

Grow Your Business, Not Your Inbox

Stay informed and join our daily newsletter now!
Will be used in accordance with our Privacy Policy
'Pharma Bro' Martin Shkreli Arrested on Securities Fraud Charges
Image credit: Getty Images
Martin Shkreli, the now-notorious CEO of Turing Pharmaceuticals.
1 min read
This story originally appeared on Fortune Magazine

Martin Shkreli, the now-notorious CEO of Turing Pharmaceuticals, has been arrested on suspicion of securities fraud, according to Bloomberg News.

Shkreli, 32, became infamous earlier this year when he drastically raised the price of a drug taken by AIDS patients, but Bloomberg said the case against him is unrelated to that.

Instead, prosecutors have charged him with illegally taking stock from Retrophin Inc., a biotech firm which he founded in 2011, and using it to pay off unrelated business debts, Bloomberg said.

Shkreli’s hedge fund MSMB Capital Management suffered heavy losses as a result of the fraud, the agency added, referring also to allegations of “secret payoffs” and “sham consulting arrangements.”

More from Entrepreneur

Get heaping discounts to books you love delivered straight to your inbox. We’ll feature a different book each week and share exclusive deals you won’t find anywhere else.
Jumpstart Your Business. Entrepreneur Insider is your all-access pass to the skills, experts, and network you need to get your business off the ground—or take it to the next level.
Create your business plan in half the time with twice the impact using Entrepreneur's BIZ PLANNING PLUS powered by LivePlan. Try risk free for 60 days.

Latest on Entrepreneur

Entrepreneur Media, Inc. values your privacy. In order to understand how people use our site generally, and to create more valuable experiences for you, we may collect data about your use of this site (both directly and through our partners). By continuing to use this site, you are agreeing to the use of that data. For more information on our data policies, please visit our Privacy Policy.